Transcatheter Aortic Valve Replacement Market Size, Share & Trends Analysis Report By Implantation Procedure (Transaortic, Transfemoral, Transapical), By Material (Nitinol, Cobalt Chromium), By Mechanism, By End-use, By Region, And Segment Forecasts, 2025

Transcatheter Aortic Valve Replacement Market Summary

The global transcatheter aortic valve replacement market size was estimated at USD 6.83 billion in 2024 and is projected to reach USD 11.76 billion by 2033, growing at a CAGR of 5.99% from 2025 to 2033. Factors driving the demand for transcatheter aortic valve replacement (TAVR) include the rising prevalence of aortic valve stenosis (AS), increasing preference for minimally invasive procedures, and the growing geriatric population.

According to an NCBI article published in February 2023, aortic stenosis is a structural heart condition characterized by a hemodynamic obstruction at the aortic valve, impeding blood flow. Among its various causes, calcific stenosis (CAS) is the most prevalent and is estimated to affect approximately 12.6 million people globally. This includes a significant prevalence rate of 1,841 cases per 100,000 adults aged 70 and older, highlighting its impact on the aging population.

The global increase in the geriatric population is another key market driver. Older adults are more susceptible to cardiovascular diseases, which necessitates effective treatment options. According to the World Health Organization article published in October 2024, the proportion of the world's population over 60 years old is expected to double by 2050, reaching approximately 2.1 billion. The global population of individuals aged 80 years and older is projected to experience a threefold increase from 2020 to 2050, reaching an estimated total of 426 million. This demographic shift means more elderly patients will require medical interventions for age-related conditions. The elderly are often high-risk candidates for conventional surgical procedures, making the less invasive procedures a more viable and safer alternative.

The rising adoption of TAVR systems for minimally invasive aortic stenosis treatment drives market growth. Strong clinical outcomes and benchmark-surpassing results reinforce confidence in wider adoption. In July 2025, Johns Hopkins Aramco Healthcare (JHAH) reported that its outcomes beat U.S. benchmarks: 26% of patients stayed in hospital longer than three days after TAVR (versus the U.S. benchmark of <30%), 8.5% required a new pacemaker (within the U.S. benchmark range of 7-12%), general anesthesia was used in 28% of cases (target <30%), and 91% of patients were discharged home (versus a benchmark of >90%).

In addition, technological advancements in TAVR procedures significantly contribute to market growth. Innovations in valve design, catheter technologies, and imaging techniques have improved the safety, efficacy, and accessibility. For instance, in January 2023, Abbott revealed that the U.S. FDA approved its newest TAVR system, Navitor, for treating high-risk individuals undergoing open-heart surgery. Advanced imaging technologies, such as 3D echocardiography and CT scans, enable precise planning and execution of the procedure, minimizing complications. In addition, improvements in catheter technology allow for smaller, more flexible catheters, further reducing the procedure's invasiveness. These technological advancements enhance patient outcomes and expand the potential patient pool by making TAVR a feasible option for those previously deemed ineligible.

Furthermore, in May 2024, Edwards Lifesciences introduced the Sapien 3 Ultra Resilia valve in Europe, marking a milestone as the first TAVR system to integrate the company’s advanced Resilia tissue technology. Engineered to treat conditions such as native calcific stenosis and failed bioprosthetic valves, the system caters to patients across different surgical risk categories, including those deemed unsuitable for open-heart surgery. This innovative technology is poised to enhance patient outcomes by offering a minimally invasive alternative, encouraging greater system adoption, and driving market expansion.

Global Transcatheter Aortic Valve Replacement Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels, and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global transcatheter aortic valve replacement market report based on implantation procedure, material, mechanism, end-use, and region:

• Implantation Procedure Outlook (Revenue USD Million, 2021 - 2033)
• Transfemoral
• Transapical
• Transaortic
• Material Outlook (Revenue USD Million, 2021 - 2033)
• Nitinol
• Cobalt Chromium
• Stainless Steel
• Others
• Mechanism Outlook (Revenue USD Million, 2021 - 2033)
• Balloon-expandable
• Self-expandable
• End-use Outlook (Revenue USD Million, 2021 - 2033)
• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Please note The report will be delivered in 2-3 business days upon order notification. Show more